LIPELLA PHARMACEUTICALS INC.
LIPO · OTCMCIK 1347242fmd_0TCBPZJFHVC29J6RFW8N58SCWVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Sep 30, 2025, 16 periods
Latest annual · FY2024
Millions- Total revenues
- 1
- Operating income
- (5)
- Net income
- (5)
- Free cash flow
- (3)
Latest quarter · Q3 FY2025
Millions- Total revenues
- 0
- Operating income
- (1)
- Net income
- (1)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- +27.4%
LIPELLA PHARMACEUTICALS INC. (LIPO) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | $536,357 | $449,617 | +19.3% | 10-K 2025-03-28 · proof |
| Operating income | -$5.1 million | -$4.7 million | 10-K 2025-03-28 · proof | |
| Net income | -$5 million | -$4.6 million | 10-K 2025-03-28 · proof | |
| Cash from operating activities | -$4 million | -$3.2 million | 10-K 2025-03-28 · proof | |
| Total assets | $2.7 million | $3.6 million | -25.3% | 10-K 2025-03-28 · proof |
| Total liabilities | $754,417 | $432,726 | +74.3% | 10-K 2025-03-28 · proof |
| Cash and cash equivalents | $2.2 million | $3.3 million | -33.7% | 10-K 2025-03-28 · proof |
- What was LIPELLA PHARMACEUTICALS INC. (LIPO)'s revenue in fiscal 2024?
- LIPELLA PHARMACEUTICALS INC. (LIPO) reported revenue of $536,357 for fiscal 2024 (the year ended Dec 31, 2024), against $449,617 the year before (+19.3%). Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
- What was LIPELLA PHARMACEUTICALS INC. (LIPO)'s operating income in fiscal 2024?
- LIPELLA PHARMACEUTICALS INC. (LIPO) reported operating income of -$5.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$4.7 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
- What was LIPELLA PHARMACEUTICALS INC. (LIPO)'s net income in fiscal 2024?
- LIPELLA PHARMACEUTICALS INC. (LIPO) reported net income of -$5 million for fiscal 2024 (the year ended Dec 31, 2024), against -$4.6 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
- What was LIPELLA PHARMACEUTICALS INC. (LIPO)'s cash from operating activities in fiscal 2024?
- LIPELLA PHARMACEUTICALS INC. (LIPO) reported cash from operating activities of -$4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$3.2 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
- What are LIPELLA PHARMACEUTICALS INC. (LIPO)'s total assets?
- As of Dec 31, 2024, LIPELLA PHARMACEUTICALS INC. (LIPO) reported total assets of $2.7 million, against $3.6 million a year earlier (-25.3%). Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
- What are LIPELLA PHARMACEUTICALS INC. (LIPO)'s total liabilities?
- As of Dec 31, 2024, LIPELLA PHARMACEUTICALS INC. (LIPO) reported total liabilities of $754,417, against $432,726 a year earlier (+74.3%). Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
- What are LIPELLA PHARMACEUTICALS INC. (LIPO)'s cash and cash equivalents?
- As of Dec 31, 2024, LIPELLA PHARMACEUTICALS INC. (LIPO) reported cash and cash equivalents of $2.2 million, against $3.3 million a year earlier (-33.7%). Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:LIPO&period_type=annual&limit=5"Information only, not investment advice.